EyePoint, Inc. - 8-K Filing

EyePoint posted an updated investor presentation on September 10, 2026 highlighting LUGANO Phase 3 data for DURAVYU in wet AMD and plans to file a New Drug Application by H1 2027. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $EYPT

Read the full article at SEC EDGAR

More Regulatory news